Raptor Signs License Agreement With Uni Pharma To Commercialise Convivia

Convivia is designed to reduce systemic acetaldehyde exposure and related symptoms in liver enzyme aldehyde dehydrogenase (ALDH2) deficiency, or ethanol intolerance, following alcohol consumption.

As per the terms of the agreement, Raptor is expected to license Uni Pharma under all relevant patent applications, trademarks and future patents controlled by Raptor to market Convivia in Taiwan, with an option to expand the license to South Korea under the same terms.

Uni Pharma is expected to conduct a clinical trial and will register Convivia for drug licensure for existing indications.

Further, Uni Pharma is expected to carry out the marketing and sales activities for the commercialisation of Convivia.

Ted Daley, president of Raptor, said: “We believe Convivia is an exciting product candidate that could become the first approved treatment for ALDH2 deficiency, a disorder that affects approximately 50 percent of East Asian populations. This is the first of what we expect will be a franchise of out= licensing transactions to develop Convivia in various countries throughout East Asia.”

Terry Lin, general manager of Uni Pharma, said: “Convivia represents exactly what Uni Pharma looks for in a licensing candidate – a drug supported by a strong clinical history that has the potential to serve a large patient population.

“We welcome the opportunity to work with Raptor to further Convivia through the clinic and, if all goes well, commercialize the drug in Taiwan and South Korea.”